The Authors Respond

Affiliations

¹ Medical Lead Department, Translational Research in Oncology (TRIO), Montevideo, Uruguay, gonzalo.spera@trioncology.org Medical Lead Department, Translational Research in Oncology (TRIO), Montevideo, Uruguay Biostatistics, Translational Research in Oncology (TRIO), Edmonton, Canada Department of Oncology, University of Alberta, Edmonton, Canada.

Comment

Gonzalo Spera et al. Epidemiology. 2018 Sep.

. 2018 Sep;29(5):e40.

doi: 10.1097/EDE.0000000000000854.

¹ Medical Lead Department, Translational Research in Oncology (TRIO), Montevideo, Uruguay, gonzalo.spera@trioncology.org Medical Lead Department, Translational Research in Oncology (TRIO), Montevideo, Uruguay Biostatistics, Translational Research in Oncology (TRIO), Edmonton, Canada Department of Oncology, University of Alberta, Edmonton, Canada.

No abstract available

Comment on

Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study.
Spera G, Fresco R, Fung H, Dyck JRB, Pituskin E, Paterson I, Mackey JR. Spera G, et al. Ann Oncol. 2017 Aug 1;28(8):1836-1841. doi: 10.1093/annonc/mdx264. Ann Oncol. 2017. PMID: 28520849 Clinical Trial.
Re: Beta Blockers and Improved Progression-Free Survival in Patients With Advanced HER2 Negative Breast Cancer.
Sørensen GV, Cronin-Fenton DP, Sørensen HT, Damkier P, Ejlertsen B, Christiansen PM, Lash TL, Ahern TP. Sørensen GV, et al. Epidemiology. 2018 Sep;29(5):e39-e40. doi: 10.1097/EDE.0000000000000853. Epidemiology. 2018. PMID: 29771735 No abstract available.